VODG Stock News Vitro Diagnostics (VODG) 0.1800 07/25/2014 0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vitro Diagnostics (VODG) 0.1800 $VODG

Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America
ACCESSWIRE - Wed Jul 09, 11:00AM CDT
Golden, CO / ACCESSWIRE / July 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies' commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.

Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants
ACCESSWIRE - Tue Jun 10, 8:34AM CDT
Golden, Colorado / ACCESSWIRE / June 10, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, has been pursuing the determination of therapeutic benefits derived from activation of adult stems residing within the human body. This approach is advantageous over transplantation since many of the complications are overcome including, effects of in-vitro stem cell expansion, effects of allogeneic cells and regulatory obstacles. Recent research has validated and expanded the scope of this approach by reports of increased muscle performance & endurance as well as reported changes critical learning periods that may be due to activation of neural stem cells in the adult brain. It is thus likely that activation of adult stem cells leads to specific performance enhancement as is well-known for activation of blood (hematopoietic) stem cells by growth factors that stimulate generation of red or white blood cells. We have published 2 new blogs providing more detail regarding stem cell therapy without transplants http://vitrobiopharma.com/2014/06/06/stem-cel...nt-status/.

Vitro Biopharma Products Advance Pancreatic Cancer Research
ACCESSWIRE - Tue Mar 11, 9:08AM CDT
Golden, Colorado / ACCESSWIRE / March 11, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches. Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is resistant to conventional therapies. It has recently become apparent that cancer tumor cells are closely associated with other cells called cancer associated fibroblasts or CAFs. These cells promote the malignant process and block immune surveillance. CAFs are thus new drug targets for pancreatic and other cancer therapies. Vitro Biopharma products were used in recent research regarding pancreatic stellate cells, a CAF that is gaining considerable interest for new treatment options through advanced understanding of cancer biology.

10-K: VITRO DIAGNOSTICS INC
Edgar Online - Wed Feb 12, 3:26PM CST
ITEM 7.

Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
ACCESSWIRE - Tue Feb 11, 9:19AM CST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.

Vitro Biopharma Expands its Product Lines While Targeting New Stem Cell Markets
ACCESSWIRE - Tue Sep 10, 7:00AM CDT
Golden, Colorado - (ACCESSWIRE - September 10, 2013) - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its current product lines and product development in additional market segments including drug discovery & development together with select opportunities within regenerative medicine market sectors. Vitro's present products target markets within stem cell and cancer research. We provide basic research tools including cell lines, cell culture media and assays of cellular function. We have recently added cancer-associated fibroblast cell lines and novel cell culture media formulations broadening our product offerings for research. Cancer-associated fibroblasts (CAFs) are non-tumor cells within cancerous tumors that promote tumor growth and metastasis.

OTC Daily Alert Stock Watch - Vitro Diagnostics, Inc. (OTCQB: VODG)
WorldStockWire - Thu Aug 29, 3:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Vitro Biopharma Appoints Established Life Science Sales Executive to Its Board of Directors
GlobeNewswire - Wed Feb 20, 12:25PM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors. Mr. Shuster is a seasoned and experienced sales executive. He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma. Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003. Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.

Vitro Biopharma Inc announces commercial availability of MSC-derived human osteoblasts, leading to faster recovery of bone fractures
M2 - Wed Jan 23, 10:44AM CST
Stem cell company Vitro Diagnostics Inc (OTCQB:VODG) said on Tuesday that it has introduced a series of osteoblasts products to accelerate bone growth, fracture healing and development of new osteoporosis drugs.

Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth
GlobeNewswire - Tue Jan 22, 8:51AM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging proced
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 35

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 83

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 80

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 5

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 55

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 92

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading

Top 5 Most Recently Viewed Articles

BGSF Stock Declines as Company Reassesses Market Strategies

Updated Category News Views 181

BGSF Faces Market Headwinds as Stock Hits 52-Week Low In the midst of a tough market landscape, BG Staffing Inc (NYSE: BGSF) has seen its stock hit a 52-week low, dropping to $5.13. This decline mirrors a significant reduction in share value, with a notable 44.7% decrease over the past year. The current economic climate has prompted a cautious approach among investors,...

Continue Reading
Datadog's Earnings Predictions and Market Outlook for 2025

Updated Category News Views 254

What to Expect from Datadog's Earnings Announcement Datadog (NASDAQ: DDOG) is gearing up to announce its latest quarterly earnings, generating considerable interest among investors. Understanding the key metrics and expectations surrounding this event can be crucial for those looking to navigate the market effectively. Analysts' Expectations for Earnings Analysts...

Continue Reading
Investors Can Join Metagenomi, Inc. Securities Class Action

Updated Category News Views 245

Understanding Opportunities for Metagenomi, Inc. Investors Investing in stocks, especially during an initial public offering (IPO), carries risks, but it also presents unique opportunities. If you have purchased shares of Metagenomi, Inc. (NASDAQ: MGX), you might be eligible for compensation as part of a class action lawsuit. This opportunity has been highlighted by...

Continue Reading
Recent Market Trends and Insights on MongoDB Options Movements

Updated Category News Views 139

A Deep Dive into MongoDB's Options Activity Recently, attention has shifted towards MongoDB (NASDAQ: MDB), as financial giants display significant bearish moves that have piqued the interest of traders and analysts alike. An examination of MongoDB's options activity has unveiled a notable pattern, indicating varied sentiments in the market. In the latest analysis, we...

Continue Reading
Sotherly Hotels Inc. Revises Dividend Tax Treatment Details

Updated Category News Views 112

Understanding Recent Changes in Dividend Tax Treatment Sotherly Hotels Inc. (NASDAQ: SOHO), a notable player in the lodging industry, has recently announced amendments regarding the estimated income tax classification for its 2024 distributions related to the Series D preferred shares. This revision, first mentioned on February 18, arises from inaccuracies found in the...

Continue Reading